Avoidable accumulation of potentially toxic levels of benzothiazoles in babies receiving intravenous therapy.
Large amounts of a compound of exogenous origin were present in the serum of premature babies receiving prolonged intravenous therapy. This compound, identified as 2-(carboxymethylthio)benzothiazole (CMB) is derived from oxidation of 2-(hydroxyethylthio)benzothiazole which is leached out of rubber components of intravenous administration sets and syringes. Serum concentrations of CMB after prolonged exposure can exceed 500 mumol/l; concentrations over 35 mumol/l were observed in 91 babies over a period of twenty-seven months. This potentially toxic accumulation can be largely avoided by judicious choice of equipment.
Meek
J H
JH
Pettit
B R
BR
D052160:Benzothiazoles; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000097:blood / Q000628:therapy*; D007263:Infusions, Parenteral / Q000009:adverse effects* / Q000295:instrumentation; D013058:Mass Spectrometry; D013806:Theophylline / Q000008:administration & dosage; D013844:Thiazoles / Q000097:blood*
D052160:Benzothiazoles; D013844:Thiazoles; C046876:2-(carboxymethylthio)benzothiazole; D013806:Theophylline